{
    "ticker": "CNTM",
    "name": "Centessa Pharmaceuticals plc",
    "description": "Centessa Pharmaceuticals plc is a clinical-stage biopharmaceutical company dedicated to advancing a diverse portfolio of innovative medicine for patients with serious diseases. Founded in 2020 and headquartered in London, Centessa is unique in its structure, leveraging a decentralized model that enables rapid development of multiple therapeutic candidates across various stages of research and development. The company is focused on addressing unmet medical needs in areas such as oncology, immunology, and rare diseases. Centessa's diverse pipeline includes multiple product candidates derived from its unique asset-centric approach, with a strong emphasis on scientific innovation and collaboration with leading experts. The company's mission is to transform the lives of patients by bringing forward potentially transformative therapies, utilizing a combination of proprietary platforms and partnerships with other biotech firms. Centessa's commitment to patients is reflected in its rigorous clinical trial programs, which are designed to evaluate the safety and efficacy of its therapies in diverse populations. As the company continues to grow, it remains focused on expanding its pipeline and advancing its candidates through clinical development, with the goal of delivering new treatment options to patients in need.",
    "industry": [
        "Biopharmaceuticals",
        "Pharmaceuticals"
    ],
    "headquarters": "London, United Kingdom",
    "founded": "2020",
    "website": "https://www.centessa.com",
    "ceo": "Samantha T. Du",
    "social_media": {
        "twitter": "https://twitter.com/CentessaPharma",
        "linkedin": "https://www.linkedin.com/company/centessa-pharmaceuticals/"
    },
    "investor_relations": "https://investors.centessa.com",
    "key_executives": [
        {
            "name": "Samantha T. Du",
            "position": "CEO"
        },
        {
            "name": "David H. U'Prichard",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology",
            "products": [
                "SerpinPC",
                "LUM-001"
            ]
        },
        {
            "category": "Immunology",
            "products": [
                "C5aR Antagonist",
                "IRR-001"
            ]
        }
    ],
    "seo": {
        "meta_title": "Centessa Pharmaceuticals plc | Innovative Biopharmaceuticals",
        "meta_description": "Centessa Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for patients with serious diseases. Explore our diverse pipeline and commitment to patient care.",
        "keywords": [
            "Centessa Pharmaceuticals",
            "Biopharmaceuticals",
            "Clinical-stage",
            "Innovative Therapies",
            "Oncology",
            "Immunology"
        ]
    },
    "faq": [
        {
            "question": "What is Centessa Pharmaceuticals known for?",
            "answer": "Centessa Pharmaceuticals is known for developing innovative biopharmaceutical therapies for serious diseases."
        },
        {
            "question": "Who is the CEO of Centessa Pharmaceuticals?",
            "answer": "Samantha T. Du is the CEO of Centessa Pharmaceuticals plc."
        },
        {
            "question": "Where is Centessa Pharmaceuticals headquartered?",
            "answer": "Centessa Pharmaceuticals is headquartered in London, United Kingdom."
        },
        {
            "question": "What are Centessa's main therapeutic areas?",
            "answer": "Centessa focuses on oncology, immunology, and rare diseases."
        },
        {
            "question": "When was Centessa Pharmaceuticals founded?",
            "answer": "Centessa Pharmaceuticals was founded in 2020."
        }
    ],
    "competitors": [
        "MRNA",
        "BMY",
        "REGN",
        "AMGN"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "SRPT",
        "PFE"
    ]
}